Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Summary

We describe the method of programming stem cells to overexpress therapeutic factors for angiogenesis using biodegradable polymeric nanoparticles. Processes described include polymer synthesis, transfecting adipose-derived stem cells in vitro, and validating the efficacy of programmed stem cells to promote angiogenesis in a murine hindlimb ischemia model.

Abstract

Controlled vascular growth is critical for successful tissue regeneration and wound healing, as well as for treating ischemic diseases such as stroke, heart attack or peripheral arterial diseases. Direct delivery of angiogenic growth factors has the potential to stimulate new blood vessel growth, but is often associated with limitations such as lack of targeting and short half-life in vivo. Gene therapy offers an alternative approach by delivering genes encoding angiogenic factors, but often requires using virus, and is limited by safety concerns. Here we describe a recently developed strategy for stimulating vascular growth by programming stem cells to overexpress angiogenic factors in situ using biodegradable polymeric nanoparticles. Specifically our strategy utilized stem cells as delivery vehicles by taking advantage of their ability to migrate toward ischemic tissues in vivo. Using the optimized polymeric vectors, adipose-derived stem cells were modified to overexpress an angiogenic gene encoding vascular endothelial growth factor (VEGF). We described the processes for polymer synthesis, nanoparticle formation, transfecting stem cells in vitro, as well as methods for validating the efficacy of VEGF-expressing stem cells for promoting angiogenesis in a murine hindlimb ischemia model.

Introduction

The overall goal of this technique is to promote therapeutic angiogenesis using non-virally programmed stem cells overexpressing therapeutic factors at the site of ischemia. Stem cells were modified ex vivo first using biodegradable nanoparticles synthesized in the lab, and then transplanted in a murine model of hindlimb ischemia to validate their potential for enhancing angiogenesis and tissue salvage.

Controlled vascular growth is an important component of successful tissue regeneration, as well as for treating various ischemic diseases such as stroke, limb ischemia, and myocardial infarction. Several strategies have been developed to promote vascular growth, including growth factor delivery and cell-based therapy.¹ Despite the efficacy observed in the animal disease models, these methods still face limitations such as the need for supraphysiological doses for growth factor delivery, or insufficient paracrine release by cells alone. One potential strategy to overcome the above limitations is to combine stem cell therapy and gene therapy, whereby stem cells are genetically programmed ex vivo prior to transplantation to overexpress desirable therapeutic factors. This approach has been demonstrated in various disease models including hindlimb ischemia², heart disease³, bone healing⁴ and neural injury⁵, etc. However, most gene therapy techniques rely on viral vectors, which are associated with safety concerns such as potential immunogenicity and insertional mutagenesis. Biomaterials mediated non-viral gene delivery may overcome these limitations, but often suffer from low transfection efficiency. To speed up the discovery of novel biomaterials for efficient non-viral gene delivery, recent studies have employed combinatorial chemistry and high-throughput screening approach. Biodegradable polymer libraries such as poly(β-amino esters) (PBAE) have been developed and screened, which led to the discovery of leading polymers with markedly enhanced transfection efficiency compared to the conventional polymeric vector counterparts.^6-7

Herein, we describe the synthesis of PBAE and verification of their ability to transfect adipose-derived stem cells (ADSCs) in vitro, followed by subsequent transplantation of genetically-modified ADSCs overexpressing vascular endothelial growth factor (VEGF) in a murine model of hindlimb ischemia. The outcomes were evaluated by tracking cell fate using bioluminescence imaging, assessing tissue reperfusion using laser Doppler perfusion imaging (LDPI), and determining angiogenesis and tissue salvage by histology.

Protocol

1. Polymer Synthesis

1. In a fume hood, weigh out 3,523 mg of butanediol diacrylate (C) and transfer to a glass scintillation vial containing a stir bar.
2. Pre-heat 5-amino-1-pentanol (32) to 90 °C to solubilize the salt, then in a fume hood, weigh out 1,533 mg 32 and add to the scintillation vial containing C. This method will result in a molar ratio of C:32 = 1:1.2.
3. Immediately place the vial containing both solutions onto a stir plate. Set stir speed at 600 rpm.
4. Transfer the scintillation vial to an oven set at 90 °C. Set stirring speed to 1,000 rpm for 4 hr. If the stir bar gets stuck, lower the speed. After 4 hr, lower speed to 300 rpm and maintain at 90 °C for another 12-16 hr.
5. Add 5 g of C32 to 10 ml of anhydrous tetrahydrofuran (THF) in a glass scintillation vial containing a stir bar. Wrap in foil and vortex on high until fully dissolved.
6. In a separate glass scintillation vial containing a stir bar, add 10 mM of Tetraethyleneglycoldiamine (122). Add 40 ml of THF.
7. Place both vials (C32 and 122) on a stir plate for 5 min then combine together. Cover in foil and leave at room temperature stirring at 400 rpm for 24 hr. The final product is termed C32-122.
8. Weigh out 5 x 50 ml Falcon tubes for each 5 g batch of C32-122. Note the mass of each tube in a notebook.
9. Transfer 30 ml of anhydrous diethyl ether to each 50 ml Falcon tube.
10. Transfer 10 ml of C32-122 to each 50 ml Falcon tube.
11. Vortex Falcon tubes vigorously then centrifuge at 2,500 rpm for 2 min. Note: The extracted polymer will collect at the base of the tube.
12. Discard the upper solution and repeat steps 1.9 and 1.11 two more times.
13. Place the open tubes containing the extracted C32-122 in the desiccator and vacuum overnight. Ensure all tubes are protected from light.
14. Weigh all tubes containing C32-122 to determine the final mass of the extracted polymer.
15. Dissolve the extracted polymer in anhydrous DMSO at a concentration of 100 mg/ml.
16. Store the dissolved polymer at -20 °C protected from light and moisture.

2. Cell Seeding

1. Pre-coat the base of a T-150 tissue culture flask with 0.1% (wt/vol) gelatin. The gelatin should remain in the flask for 30-45 min. The gelatin coating helps adhesion of ADSCs.
2. Aspirate gelatin from the pre-coated T-150 flask.
3. Add 4 x 10⁶ ADSCs (≤ passage 3) to the flask in 20 ml of DMEM containing 10% FBS, 1% Penicillin/Streptomycin and 10 ng/ml bFGF.
4. Place the T-150 flask in the incubator at 37 °C, 5% CO₂ overnight.
5. Begin transfection procedure the following day.

3. Nanoparticle Preparation and Transfection

1. The following procedure is for the preparation of nanoparticles containing 16.1 μg plasmid DNA per 1.0 x 10⁶ cells at a polymer to plasmid weight ratio of 30:1.
2. Dilute plasmid DNA (1 mg/ml, pVEGF165, Aldevron, ND, USA) to a final concentration of 120 μg/ml in sodium acetate (25 mM) in a 15 ml Falcon tube.
3. Dilute C32-122 (100 mg/ml) to a final concentration of 3.6 mg/ml in sodium acetate (25 mM) in a second 15 ml Falcon tube.
4. Combine the contents of each Falcon tubes into a single 15 ml falcon tube and vortex immediately on high for 10 sec.
5. Let the tube sit at room temperature for 10 min for nanoparticle formation to occur.
6. While incubating, replace medium in tissue culture flask with 7.8 ml fully supplemented DMEM per 1.0 x 10⁶ cells transfected.
7. Transfer the nanoparticle solution to the tissue culture flask and tilt forward and backwards to spread evenly.
8. Place the tissue culture flask in the incubator at 37 °C, 5% CO₂ for 4 hr.
9. After 2 hr, replace the nanoparticle containing media with DMEM.
10. Following a further 2 hr incubation at 37 °C, 5% CO₂, the cells are ready for in vivo injection.

4. Hindlimb Ischemia Procedure

1. All experiments were performed in accordance with the Stanford University Animal Care and Use Committee Guidelines and approved APLAC protocols. Generating the murine model of hindlimb ischemia is performed as previously described.⁸ Please refer to the reference for detailed instructions. A short description is provided below.
2. Place the mouse under anesthesia with 1-3% dosage isoflurane by inhalation and oxygen flow rate of 1 L/min. Ensure anesthetic depth by toe pinch, reduction in respiratory rate, and lethargy.
3. Remove hair from the abdominal region and both hindlimb areas of the mouse with shaving cream.
4. Make incision at center of medial thigh towards midline and then cut through overlying fat pad to expose the femoral artery.
5. Ligate the artery at two sites: distal site (close to the knee) and proximal site (just distal to the inguinal ligament).
6. To create the ligations, separate the artery from the vein and thread a 5-0 silk suture around the artery. Tie off the artery with two knots to make the ligation.
7. Remove the artery between the two ligation points.
8. Wash the surgical area with PBS and then suture the incision closed.
9. The anesthesia can now be removed. Keep the mouse warm until re-awakening. For post-operative care, 2-4 mg/kg Lidocaine can be injected subcutaneously at the incision site prior to re-awakening. Further pain management may include subcutaneous delivery of 0.05-0.1 mg/kg Buprenorphine at 12 and 24 hr. Monitor the health status of the mice once a day for seven days by observing changes in breathing pattern, overt pain or distress, and skin color.
10. Confirm hindlimb ischemia by laser Doppler perfusion imaging.

5. Cell Injections

1. When the transfected cells and the mice are ready, wash transfected cells with PBS, trypsinize, centrifuge, and then count.
2. Resuspend cells at a density of 10 x 10⁶ cells per ml in PBS.
3. Cell suspensions should be separated into separate Eppendorf tubes at a volume of 110 μl. This will ensure that each mouse receives an equal amount of cells.
4. Place each mouse under anesthesia (2.5% isoflurane, 1 L/min oxygen flow rate).
5. Clean the injection site with alcohol wipes.
6. Utilizing a 27 G tuberculin syringe, draw the cells up and down into the syringe to ensure a homogeneous suspension is achieved. Draw up 100 μl of the cell suspension volume into the syringe.
7. Inject half the cell suspension into the adductor muscle region and then inject the other half into the calf muscle region. Upon injecting, leave the syringe in place for at least 15-30 sec to prevent leakage of the cell suspension.
8. Proper controls for the animal study include: 1) cells transfected with a non-coding plasmid (e.g. plasmid with no biological activity); 2) cells alone; and 3) PBS.
9. When injections are complete, remove the mouse from anesthesia and keep warm until the mouse re-awakes.

6. Bioluminescence Imaging

1. To begin bioluminescence imaging (BLI), anesthetize mice as described above.
2. Clean the injection site with alcohol wipes.
3. Utilizing insulin syringe, load 100 μl of 15 mg/ml D-luciferin (the substrate for firefly luciferase). Keep substrate away from light.
4. To perform intraperitoneal injections, hold mice by the skin of their back to pull their anterior skin taut. Insert needle intraperitoneally into the abdominal region and inject 100 μl of substrate.
5. Place the mouse in the IVIS luciferase imaging chamber under anesthesia.
6. Image the mice with an exposure time of 1.0 min. When parameters are set, begin to acquire images.
7. When the image is acquired, mark the region of interest to measure the luciferase signal. In this case, mark the ischemic limb at the cell-injection site.
8. Continue to measure the luciferase signal every 3-5 min until the signal reaches a peak and begins to decline. This is the value utilized for comparison across mice and over several time points.
9. When complete, remove the mice from the chamber and anesthesia. Keep mice warm until re-awakening.

7. Laser Doppler Perfusion Imaging

1. Laser Doppler perfusion imaging is performed as previously described.⁸ The procedure is briefly described here.
2. Prior to Doppler imaging the mouse should be cleanly shaven at the areas overlying both hindlimbs and the abdominal region to prevent artifact due to hair.
3. When prepared to Doppler image, the mouse should be anesthetized as described above.
4. Warm the mouse to 36 °C on a hot plate while monitoring body temperature by rectal thermometer.
5. Place the mouse on a non-reflective black surface and keep anesthetized by nose cone. The mouse should be placed on its dorsal surface with its limbs exposed evenly.
6. Position the laser Doppler sensor roughly 15 cm above the mouse and directing the laser pointer from the sensor towards the groin region of the mouse.
7. When the mouse and the Doppler sensor are in position, images can be taken utilizing the LDPIwin software by pressing the Start button.
8. Relative perfusion measurements could be taken by indicating both hindlimbs (ischemic and non-ischemic) as region of interests (ROI). The ratio of mean perfusion of the ischemic to the non-ischemic hindlimb will indicate relative perfusion.

8. Tissue Harvest Procedure

1. When prepared to harvest mouse tissue for histology and/or biochemical processing, the mouse should be euthanized. Here, the mouse is euthanized by exposing to 5% isoflurane for 3-5 min, then euthanizing the mouse by cervical dislocation.
2. Cut the overlying skin surrounding the hindlimb circumferentially at the distal abdominal region and proximal to the hindlimb. The skin is cut from the ventral to the dorsal surfaces, such that the skin can be pulled back over the hindlimb to the foot.
3. Upon pulling the skin back, the limb could be amputated by utilizing blunt dissection scissors to cut at the pelvic and femur joint.
4. Two main tissues are taken for analysis: the medial adductor muscles and the gastrocnemius muscles.
5. For histology, embed one or both tissues in optimal cutting temperature (OCT) for cryosectioning.
6. For biochemical analysis, collect one or both tissues into an 1.5 ml Eppendorf and submerge into a bath of liquid nitrogen for at least 2 min. The samples can be stored at -80 °C for future processing.

Results

Upon mixing together, the positively-charged polymer (C32-122) and negatively-charged DNA plasmid self-assembles into nanoparticles. Nanoparticle formation may be confirmed through electrophoresis analysis i.e. the complexation between C32-122 and plasmid DNA will prevent mobilization of the DNA during electrophoresis. The polymer serves as a transfection reagent to facilitate enhanced uptake of DNA into the target cells and the subsequent expression of encoding proteins (Figure 2). Cells can be...

Discussion

Here we report a method to program adult stem cells to overexpress therapeutic factors using non-viral, biodegradable nanoparticles. This platform is particularly useful for treating diseases where stem cells can naturally home, such as ischemia and cancer.^9-10 Furthermore, the non-viral gene delivery platform allows for transient overexpression of therapeutic factors, which is suitable for most tissue regeneration and wound healing processes. The transfection process depends upon efficient DNA entry into cell...

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
DMEM	Invitrogen	11965
Fetal Bovine Serum	Invitrogen	10082
Penicillin/Streptomycin	Invitrogen	15070
Basic Fibroblast Growth Factor	Peprotech	100-18B
1,4-Butanediol Diacrylate (90 %)	Sigma Aldrich	411744	Acronym: C
5-amino-1-pentanol (97 %)	Alfa Aesar	2508-29-4	Acronym: 32
Tetraethyleneglycoldiamine >99 %)	Molecular Biosciences	17774	Acronym: 122
Sodium Acetate	G-Biosciences	R010
Phosphate Buffered Saline	Invitrogen	14190-144
Tetrahyofuran Anhydrous (>99.9 %)	Sigma Aldrich	401757
Diethyl Ether Anhydrous (>99 %)	Fisher Scientific	E138-4
DMSO Anhydrous (>99.9 %)	Sigma Aldrich	276855
Gelatin	Sigma Aldrich	G9391
Trypsin-EDTA	Invitrogen	25200
D-luciferin	GoldBio
Optimal Cutting Temperature (O.C.T)	Tissue-Tek	4583
Rat anti-Mouse CD31	BD Pharmingen	550274
Alexa Fluor 594 anti-rat IgG	Invitrogen	A11007